Michael B. Maris - Concepedia

Author

Michael B. Maris

Also Known As

M B Maris, M Maris, M. B. Maris, M. MARIS, M. Maris, M.B. Maris, MICHAEL MARIS, Michael B Maris, Michael B. Maris, Michael Maris

244

Publications

16.7K

Citations

H-Index

125

Concepts

All Affiliations

Fred Hutch Cancer Center University of Washington Stanford University Colorado Blood Cancer Institute Sarah Cannon

About

Michael B. Maris is an author at Fred Hutch Cancer Center specializing in medicine, hematology, and transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	29	2.2K
2	Health Sciences	13	16	945
3	Engineering	5	5	211
4	Public Health	1	1	320
5	Social Sciences	1	1	95

Michael B. Maris

118

Publications

16K

Citations

H-Index

Page 1

	Year	Citations
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Blood	2005	2.9K
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation Marco Mielcarek, Paul J. Martin, Wendy M. Leisenring, Blood	2003	555
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning Takahiro Fukuda, Michael Boeckh, Rachel A. Carter, Blood	2003	464
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases Dietger Niederwieser, Michael B. Maris, Judith A. Shizuru, Blood	2003	455
Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation Mohamed L. Sorror, Rainer Storb, Brenda M. Sandmaier, Journal of Clinical Oncology	2014	413
Comorbidity and Disease Status–Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation Mohamed L. Sorror, Brenda M. Sandmaier, Barry E. Storer, Journal of Clinical Oncology	2007	395
Quantitation of time- and frequency-resolved optical spectra for the determination of tissue oxygenation Eva Sevick, B. Chance, J.S. Leigh, Analytical Biochemistry	1991	363
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies Michael B. Maris, Dietger Niederwieser, Brenda M. Sandmaier, Blood	2003	335
Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning Frédéric Baron, Michael B. Maris, Brenda M. Sandmaier, Journal of Clinical Oncology	2005	333
Hematopoietic cell transplantation (HCT)-specific-comorbidity index: A new tool for risk assessment before allogeneic HCT Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Biology of Blood and Marrow Transplantation New ToolPrognosisPopulation Health SciencesValidation SetLogistic Analysis	2005	320

Page 1